Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis

Published:2017-11-26 Issue:3 Volume:58 Page:386-398
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Wei Xiaohui¹,Gibiansky Leonid²,Wang Yehong¹,Fuh Franklin³,Erickson Rich⁴,O'Byrne Sharon⁵,Tang Meina T.¹

Affiliation:

1. Clinical Pharmacology Genentech South San Francisco CA USA

2. QuantPharm LLC North Potomac MD USA

3. Biomarkers, Genentech South San Francisco CA USA

4. Bioanalytical Sciences, Genentech South San Francisco CA USA

5. Early Clinical Development, Genentech South San Francisco CA USA

Funder

Genentech

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1031

Reference19 articles.

1. Inhibition of Selective Adhesion Molecules in Treatment of Inflammatory Bowel Disease

2. Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention

3. Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel Disease

4. bidirectional, allosteric signaling machines;Integrins Hynes RO.;Cell,2002

5. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells;Cepek KL;J Immunol,1993

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells;Inflammatory Bowel Diseases;2022-07-11

2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial;The Lancet Gastroenterology & Hepatology;2022-02

3. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study;The Lancet Gastroenterology & Hepatology;2022-02

4. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study;The Lancet Gastroenterology & Hepatology;2022-01

5. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials;The Lancet Gastroenterology & Hepatology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3